Dr. Nihal Essa Abdulla, MD

Dr. Abdulla practices at Cancer and Blood Specialty Clinic in Los Alamitos, California.

Dr. Abdulla's NPI, 1750585345, was assigned on June 14, 2007. Dr. Abdulla graduated from Dow University of Health Sciences in 2000. Dr. Abdulla holds California license A120904.

Dr. Abdulla's primary practice is Cancer and Blood Specialty Clinic, at 3851 Katella Ave, Los Alamitos, CA 90720 in Orange County. The practice phone is (627) 254-3675.

Dr. Abdulla's primary practice is Cancer and Blood Specialty Clinic in Los Alamitos, California. Dr. Abdulla is also affiliated with UCI Health - Orange. The medical group on file is MemorialCare Medical Group. Dmand AI also links Dr. Abdulla to 4 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abdulla practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Abdulla's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Abdulla is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Abdulla's licenses on file in 2 states: California and Texas.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphedema and lymphoma among the conditions Dr. Abdulla treats.

CMS data shows 10,521 Medicare services from Dr. Abdulla across 18 procedure codes in 2024, for 391 Medicare patients. Medicare paid $324,074 for them.

CMS counts 391 Medicare patients who saw Dr. Abdulla in 2024. The largest group is 65 to 74, with 154 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abdulla's median patient age at 72, with 60% women.

In 2024, Dr. Abdulla wrote 1,747 Medicare Part D claims for 277 patients. 71% of them were for generic drugs. CMS names the drug for 1,386 of them, across 38 drugs with 11 or more claims each, at $2,870,196 in total drug cost. In 2023, CMS named 1,242 claims across 35 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Abdulla for performance year 2024, reported as part of a group. Dr. Abdulla accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abdulla as offering telehealth.

Dmand AI links 6 papers to Dr. Abdulla, published from 2011 to 2023. The most frequent topics are Antineoplastic Agents. Dr. Abdulla's most frequent co-authors are Shehzad N. Merwat, MD, Kareem Husam Abdelhadi, MD and Luca Cicalese, MD.

Dmand AI links Dr. Abdulla to 6 clinical trials, 3 of them phase 1/2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Adenocarcinoma of Lung. Lantern Pharma Inc. sponsors the most, 3. Open Payments lists research payments to Dr. Abdulla that name 1 trial.

CMS Open Payments shows 1,502 general payments to Dr. Abdulla from 100 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 64% of the total. AstraZeneca Pharmaceuticals LP paid the most, $7,303. It also lists 1 research payment totaling $481 in 2021, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Abdulla.

Dr. Abdulla graduated from Dow University of Health Sciences in 2000. Dr. Abdulla is a member of ACP and ASCO.

Dr. Abdulla is in network with 13 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.